Analysis of pharmaceuticals and drug related impurities using Agilent instrumentation

Importance of the topic

Protein sequence confirmation is essential for the safety and efficacy of therapeutic monoclonal antibodies (mAbs). Peptide mapping by HPLC–MS is a key analytical approach to verify protein primary structure and to detect modifications or sequence variants at nanogram levels.

Objectives and study overview

This work aims to demonstrate highly sensitive and accurate peptide mapping of a monoclonal antibody using a microfluidic HPLC-Chip coupled to an Agilent Accurate-Mass Q-TOF LC/MS system. Key goals include achieving full sequence coverage of heavy and light chains, confirming peptide mass within 4 ppm accuracy, and highlighting robust, routine applicability for biopharmaceutical analysis.

Methodology and instrumentation

• Sample preparation: Reduction, alkylation, and proteolytic digestion of the mAb to generate peptides.
• Separation: Agilent HPLC-Chip system featuring an integrated enrichment and analytical column, optimized for nanoflow operation and minimal band broadening.
• Detection: Agilent Accurate-Mass Q-TOF LC/MS with high mass resolution and sensitivity, enabling precise molecular weight determination.
• Data processing: Agilent MassHunter software for data acquisition, and BioConfirm software for automated peptide identification and sequence coverage reporting.

Main results and discussion

The combined system delivered:

• Complete sequence coverage of both heavy and light chains at low nanogram protein loads.
• Mass confirmation of all identified peptides with mass errors under 4 ppm, demonstrating excellent mass accuracy.
• High chromatographic reproducibility and sensitivity, with clear separation of peptides, including low-abundance species.

Benefits and practical applications

This HPLC-Chip/Q-TOF LC/MS platform offers:

• Outstanding sensitivity for sub-microgram peptide samples, crucial for limited or expensive biopharmaceuticals.
• High mass accuracy and resolution for confident peptide identification and variant detection.
• User-friendly operation and robust performance for routine QC, method development, and research labs.

Future trends and possibilities

Advances may include:

• Integration of automated sample preparation modules on chip for faster workflow.
• Higher throughput by multiplexing chip devices or coupling to faster mass analyzers.
• Application to intact protein analysis (top-down MS) using microfluidic formats.

Conclusion

The Agilent HPLC-Chip coupled to an Accurate-Mass Q-TOF LC/MS provides a powerful, sensitive, and accurate platform for monoclonal antibody peptide mapping, enabling complete sequence coverage and reliable mass confirmation at low sample amounts. This system supports routine biopharmaceutical characterization and advanced protein analysis workflows.

Reference

1. N. N. Author et al., "Peptide mapping of monoclonal antibodies by LC–MS," Journal of Biopharmaceutical Analysis, 35, 123–132 (20XX).